Tech News: Major breakthrough in Covid therapy
By Opinion
Share
With a looming third wave of Covid-19 in South Africa and even a fourth wave elsewhere in the world, scientists around the world are working hard to find and develop treatments for the destructive coronavirus.
Since the discovery of the virus in Wuhan in December 2019 there have been more than 165 million cases of Covid-19 across the world, resulting in 3.4 million deaths.
Off-label drugs modestly effective
Until now, the drugs used in the treatment of Covid-19 that were originally used for other purposes (“off-label” use), such as dexamethasone (a glucocorticoid used for rheumatism, asthma, chronic obstructive lung disease), remdesivir (a broad-spectrum antiviral drug to treat Ebola), hydroxychloroquine (to treat malaria), lopinavir and ritonavir (to treat HIV), favilavir (to treat inflammation in the nose and throat), molnupiravir (originally used for flu), heparin/enoxaparin (anticoagulants), and ivermect
An international team of scientists, from Australia and the US, has developed an experimental direct-acting antiviral therapy that can reduce viral load by
New antiviral with 99.9% efficacy against Covid-19 developed
By IANS |
0 Views
New antiviral with 99.9% efficacy against Covid-19 developed. Image Source: IANS News
Sydney, May 19 : An international team of scientists, from Australia and the US, has developed an experimental direct-acting antiviral therapy that can reduce viral load by 99.9 per cent and may be a new treatment against Covid-19.
Traditional antivirals, which include Tamiflu, zanamivir and remdesivir, reduce symptoms and help people recover earlier.
The new antiviral approach used gene-silencing RNA technology called siRNA (small-interfering RNA) to attack the virus genome directly, which stops the virus from replicating, as well as lipid nanoparticles designed at Griffith University and City of Hope to deliver the siRNA to the lungs, the critical site of infection.
Read more about New antiviral with 99.9% efficacy against coronavirus developed on Business Standard. An international team of scientists, from Australia and the US, has developed an experimental direct-acting antiviral therapy that can reduce viral load by 99.9%